Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Congenital Adrenal Hyperplasia · Carcinoid Syndrome · CRNX

Crinetics Pharmaceuticals Europe

Crinetics Pharmaceuticals Europe GmbH

Crinetics Pharmaceuticals Europe patent portfolio — 26 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
6055 Lusk Blvd, San Diego, California 92121, US HQ
2008 Founded
597 Employees
Public company Type
CRNX · NYSE Ticker
Company details
Status
Public
HQ
6055 Lusk Blvd, San Diego, California 92121, US
Founded
2008
Employees
597
Programs
12
Drugs
4
Patents
26
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Crinetics Pharmaceuticals Europe patents

26 pharmaceutical patents indexed for Crinetics Pharmaceuticals Europe. 0 expire within 24 months.

Crinetics Pharmaceuticals Europe has 26 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

26 patents

Patent portfolio

  1. US 12280046

    Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12208092

    Compositions and methods for administering paltusotine to patients with hepatic impairment

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12134610

    Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11957674

    Formulations of a somatostatin modulator

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11834462

    Somatostatin modulators and uses thereof

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11773076

    Crystalline forms of a somatostatin modulator

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11608335

    Somatostatin modulators and uses thereof

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11566015

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11479540

    Nonpeptide somatostatin type 5 receptor agonists and uses thereof

    Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11414397

    Somatostatin modulators and uses thereof

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11266641

    Formulations of a somatostatin modulator

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11186590

    Somatostatin modulators and uses thereof

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11072598

    Somatostatin modulators and uses thereof

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11028068

    Somatostatin modulators and uses thereof

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10981894

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10889561

    Process of making somatostatin modulators

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10875839

    Somatostatin modulators and uses thereof

    Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10766877

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10696689

    Somatostatin modulators and uses thereof

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10604507

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10597377

    Somatostatin modulators and uses thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10562884

    Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10464918

    Process of making somatostatin modulators

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10351547

    Somatostatin modulators and uses thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9902703

    Somatostatin modulators and uses thereof

    Expires Mon Feb 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9896432

    Somatostatin modulators and uses thereof

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Crinetics Pharmaceuticals Europe have?

26 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Crinetics Pharmaceuticals Europe patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.